International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 1.7.2021
students studying with masks
doctor giving vaccine shot to elderly
Optimism for an Uncertain 2021
As we head into a new year, new COVID-19 vaccines promise to restore normalcy. But when? And what can myeloma patients do to remain safe meanwhile? IMF Chairman Dr. Brian G.M. Durie offers some answers.
fda stamp
FDA Approves XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After at Least One Prior Therapy
The U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
pharmacy cabinet
NCCN Adds Three XPOVIO® (Selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
The National Comprehensive Cancer Network® (NCCN) added three different XPOVIO®(selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for previously treated multiple myeloma.
Submission of Biologics License Application to FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Myeloma Has Been Initiated
On December 21, 2020, a rolling submission of the Biologics License Application to the U.S. Food and Drug Administration for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed and/or refractory multiple myeloma, was initiated.
Best of ASH 2020
Register NOW for the Best of ASH 2020 Webinar
Dr. Brian G.M. Durie discusses key takeaways from the 2020 American Society of Hematology (ASH) annual conference for patients, caregivers, and others. Save the date: Thursday January 14, 2021, at 4:00 p.m. PT / 7:00 p.m. ET for this webinar featuring an ASH summary.
register button
And This Too Shall Pass…
Once again, the IMF is hosting a raffle for a 10-day stay at the Villa Ono Oasis in historic Kailua-Kona, Hawaii. While many of us have been affected by COVID-19, we hope to remind you that this too shall pass. If you purchase the winning $50 raffle ticket, you could find yourself just minutes from the Hawaiian coastline. The winner will be announced on April 2, 2021. Note: Bookings will be in the future based on mutual availability with you and the property owner.
learn more
ask doctor durie video image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

Are four-drug combinations more effective than three-drug combinations?
Watch Now
Clinical Trials
OCEAN Trial (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Search the Myeloma Matrix 2.0

Smart Patients: Join the Conversation
Upcoming Events
Watch the Replay
“IMWG Conference Series: ASH 2020”

Watch the Replay
“Living Well with Myeloma” Webinar

Watch the Replay
IMF Patient & Family Webinar

Learn More
Winter Challenge

Click here to see all events

We Thank Our Sponsors:

Amgen; Bristol-Myers Squibb; Genentech; GSK; Karyopharm Therapeutics; Oncopeptides, Inc.;
Sanofi-Genzyme; and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page